Table 1. Comparison of demographic and clinical features between RA patients with and without positive TAbs.
| Parameter | Total (n = 125) | TAbs-positive group (n = 44) | TAbs-negative group (n = 81) | pa |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Women, n (%) | 96(77) | 37(84) | 59(73) | 0.155 |
| Age (years) | 52(46–61) | 51(42–58) | 54(48–62) | 0.071 |
| Disease duration (months) | 60(12–120) | 72(24–120) | 50(12–120) | 0.235 |
| Short (<6 months), n (%) | 13(10) | 3(7) | 10(12) | 0.334 |
| Intermediate (6–24 months), n (%) | 20(16) | 7(16) | 13(16) | 0.984 |
| Long (>24 months), n (%) | 92(74) | 34(77) | 58(72) | 0.492 |
| Age of onset (years) | 46(39–53) | 42(35–49) | 47(41–55) | 0.025 |
| Smoking, n (%) | 19(15) | 7(16) | 12(15) | 0.871 |
| Disease characteristics | ||||
| TJC28 | 6(2–12) | 9(3–13) | 5(1–11) | 0.040 |
| SJC28 | 4(1–10) | 6(2–11) | 3(1–8) | 0.074 |
| Pain VAS | 4(2–6) | 4(3–6) | 4(2–6) | 0.217 |
| PtGA | 5(3–7) | 5(3–7) | 4(3–7) | 0.288 |
| PrGA | 5(3–6) | 6(3–7) | 4(2–6) | 0.081 |
| HAQ | 0.75(0.19–1.25) | 0.88(0.28–1.25) | 0.63(0.13–1.06) | 0.096 |
| Functional limitation, n (%) | 38(30) | 18(41) | 20(25) | 0.060 |
| CRP (mg/L) | 26.5(7.8–50.9) | 24.3(9.8–42.3) | 30.0(5.1–56.4) | 0.576 |
| ESR (mm/h) | 60(37–88) | 66(42–90) | 58(35–85) | 0.399 |
| RF positivity, n (%) | 90(72) | 38(86) | 52(64) | 0.008 |
| RF titer ≥ 3 ULN, n (%) | 76(61) | 34(77) | 42(52) | 0.005 |
| ACPA positivity, n (%) | 89(71) | 32(73) | 57(70) | 0.781 |
| ACPA titer ≥ 3 ULN, n (%) | 71(57) | 26(59) | 45(56) | 0.703 |
| DAS28-CRP | 4.83(3.55–5.68) | 5.10(3.89–5.75) | 4.37(3.49–5.60) | 0.076 |
| DAS28-ESR | 5.45(4.26–6.48) | 6.00(4.97–6.57) | 4.93(4.18–6.47) | 0.036 |
| SDAI | 21(10–33) | 25(16–37.8) | 18(9–31) | 0.084 |
| CDAI | 24.4(13.8–36.8) | 27.1(16.3–37.8) | 21.3(13.1–34.4) | 0.049 |
| RAPID3 | 4.03(1.97–5.39) | 4.39(2.93–5.63) | 3.75(1.78–5.09) | 0.155 |
| Radiographic status | ||||
| Bony erosion, n (%) | 116(93) | 40(91) | 76(94) | 0.547 |
| JNS subscore | 3(0–16) | 8(0–26) | 2(0–11) | 0.088 |
| JE subscore | 9(3–23) | 13(3–34) | 8(3–19) | 0.075 |
| mTSS | 11(4–37) | 19(5–62) | 9(4–31) | 0.076 |
| RJD, n (%) | 64(51) | 30(68) | 34(42) | 0.005 |
| Previous medications, n (%) | ||||
| Naiveb | 59(47) | 18(41) | 41(51) | 0.299 |
| GCs | 52(42) | 20(46) | 32(40) | 0.519 |
| MTX | 35(28) | 13(30) | 22(27) | 0.777 |
| LEF | 24(19) | 7(16) | 17(21) | 0.491 |
| SASP | 7(6) | 2(5) | 5(6) | 0.705 |
| HCQ | 10(8) | 4(9) | 6(7) | 0.740 |
| CysA | 2(2) | 0(0) | 2(3) | NA |
| Biologics | 5(4) | 2(5) | 3(4) | 0.819 |
Notes.
a
Comparison between the TAbs-positive group and the TAbs-negative group. Data are described as the median (interquartile range) unless stated otherwise.
b
Without glucocorticosteroids or disease-modifying antirheumatic drugs therapy within the previous six months.
- GCs
- glucorticosteroids
- MTX
- methotrexate
- LEF
- leflunomide
- SASP
- sulfasalazine
- HCQ
- hydroxychloroquine
- CysA
- cyclosporin A
- NA
- not applicable